TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of E7080 in Subjects With Advanced Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~1. Histologically or clinically diagnosed with thyroid cancer~2. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2~3. Adequate laboratory values/organ function tests~Exclusion criteria~Participants with following complication or disease history~1. Brain metastasis~2. Systemic severe infection~3. Significant cardiovascular impairment~4. QTc greater than 480 milliseconds~5. Active hemoptysis~6. Bleeding or thrombotic disorders~7. Having greater than 1+ proteinuria on urine dipstick testing will undergo 24 hour urine collection for quantitative assessment of proteinuria~8. Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of E7080~9. Major surgery within 3 weeks before enrollment~10. With co-existing effusion requiring drainage

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E7080 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Diflunisal on Familial Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 75 years~* Biopsy proven amyloidosis~* Genotyping of variant transthyretin~* Signs of peripheral or autonomic neuropathy~Exclusion Criteria:~* Use of other non-steroidal anti-inflammatory drugs~* Other causes of sensorimotor polyneuropathy~* Anticipated survival \<2 years or liver transplantation in \<1 yr~* Liver transplantation~* Profound nerve, heart or kidney impairment~* Pregnancy or unwillingness to use contraception by women of childbearing age~* Active or recent gastrointestinal bleeding~* Non-steroidal or aspirin drug allergy/hypersensitivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diflunisal (Type: ACTIVE_COMPARATOR): Diflunisal 250 mg po bid
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 po bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Gastric Emptying During and After COLOKIT® Intake

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject who signed an informed consent to participate in the trial.~* Subject affiliated with Social Security~* Men and women aged 18 to 75 years.~* Subject with an indication of scheduled outpatient colonoscopy.~* colonoscopy performed within six hours after the second sequence COLOKIT®.~* Subject able to swallow tablets.~Exclusion Criteria:~1. Women pregnant or likely to be (without contraception) or nursing.~2. Subject having any of the following diseases or conditions:~   * allergy or hypersensitivity to the product tested or any of its excipients,~  * nausea, vomiting or abdominal pain,~  * clinically significant renal failure,~  * primary hyperparathyroidism associated with hypercalcemia,~  * congestive heart failure,~  * ascites,~  * a known or suspected bowel obstruction,~  * megacolon (congenital or acquired)~  * intestinal perforation,~  * ileus,~  * an inflammatory disease or suspected inflammatory bowel disease,~  * swallowing disorders,~  * known digestive motor disorders (gastroparesis, scleroderma, mega-esophagus),~  * diabetes mellitus (insulin or non insulin-dependent)~  * a history of gastric surgery (partial or total)~  * a contraindication to the anesthesia required for the completion of the colonoscopy,~  * Any clinical condition which, in the opinion of the investigator, would not allow the subject to perform the test in good conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- COLOKIT® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~· Patients with rheumatoid arthritis \[only those refractory to the previous treatment\]

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with confirmed diagnosis of CF.~* Homozygous for F508del (F/F).~* Subjects who weigh ≥8 kg without shoes and wearing light clothing at the Screening Visit.~Key Exclusion Criteria:~* Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject.~* Solid organ or hematological transplantation.~* History of any illness or comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study.~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to LUM/IVA in placebo-controlled period for 48 weeks.
- Part 1: LUM/IVA (Type: EXPERIMENTAL): Participants weighing less than (\<)14 kilograms (kg) at screening received LUM 100 milligrams (mg)/IVA 125 mg fixed-dose combination (FDC) every 12 hours (q12h) in placebo-controlled period for 48 weeks. Participants weighing greater than or equals to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h in placebo-controlled period for 48 weeks.
- Part 2: Overall LUM/IVA (Type: EXPERIMENTAL): Participants who received either placebo or LUM/IVA in placebo-controlled period administered LUM/IVA (either LUM 100 mg/IVA 125 mg FDC q12h or LUM 150 mg/IVA 188 mg FDC q12h as per their body weight for participants \<6 years of age at week 48 and LUM 200 mg/IVA 250 mg FDC q12h regardless of their body weight for participants \>=6 years of age at week 48) in open-label period for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic UCB Therapy With EPO in Children With CP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with cerebral palsy~* Age of ≥10 months and ≤6 years~* Mismatch in HLA-A, B, and DR ≤2, and total nucleated cell count ≥3x107/kg. If the cell count is less than given values, more than 1 unit could be used.~* Hemoglobin ≤13.6 g/dL~* Decision of participation in the study by and acquisition of informed consent from the subject's representative~* Willingness and ability to be hospitalized according to the schedule specified in the protocol and continue the study for 12 months after study entry~Exclusion Criteria:~* Current aspiration pneumonia~* Known genetic disease~* History of hypersensitivity reaction to any study drugs pertinent to the study~* History of participation in any other study with stem cell~* Prior treatment with EPO within 3 months prior to study entry~* Known coagulopathy with family history of thrombosis or medical history of recurrent thrombosis~* Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents~* Uncontrolled hypertension defined as systolic blood pressure \>115 mmHg and/or diastolic blood pressure \>70 mmHg~* Hepatic impairment defined as asparate aminotransferase (AST) \>55 IU/L and/or alanine aminotransferase (ALT) \>45 IU/L~* Renal impairment defined as creatinine (Cr) ≥1.2 mg/dL~* Absolute neutrophil count ≤500/dL~* Presence of diagnosed or suspected malignant tumor and/or hematologic malignancy~* Non-compliance with study visits specified in the protocol or unwillingness of care-giver due to lack of understanding of the patient

- Gender: ALL
- Minimum Age: 10 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- UCB and EPO (Type: EXPERIMENTAL): UCB + EPO + Rehabilitation
- UCB and placebo EPO (Type: ACTIVE_COMPARATOR): UCB + placebo EPO + Rehabilitation
- placebo UCB and EPO (Type: ACTIVE_COMPARATOR): placebo UCB + EPO + Rehabilitation
- placebo UCB and placebo EPO (Type: PLACEBO_COMPARATOR): placebo UCB + placebo EPO + Rehabilitation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Contingency Management Intervention on Substance Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* veterans presenting for outpatient substance use disorders treatment with a diagnosis of alcohol, cocaine, amphetamine, or methamphetamine dependence~Exclusion Criteria:~* primary cannabis dependence~* primary opioid dependence~* severe psychiatric symptoms~* suicide risk~* positive history or screen for pathological gambling~* lacking transportation or living too far away to attend twice per week research appointments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contingency Management (Type: EXPERIMENTAL): Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are negative, they receive a chance to draw tokens from a bowl. Some tokens are social reinforcement. Others have monetary value.
- Placebo (Type: PLACEBO_COMPARATOR): Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-85 years (both inclusive) at the time of signing inform consent~* Subject with normal renal function or renal impairment (mild, moderate, severe or end-stage renal disease requiring dialysis)~* For subject with normal renal function: good general health (as judged by the investigator)~* Body mass index (BMI) 18.5-40.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods~* History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease~* Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)~* Any blood draw or donation of blood or plasma in excess of 400 mL within the 3 months preceding the screening visit (Visit 2)~* History of significant drug abuse, or a positive drug test at the screening visit (Visit 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with renal impairment (Type: EXPERIMENTAL): None
- Subjects with normal renal function (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Dental Pain Study Of Ibuprofen Extended Release

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 16 to 40 years of age~* Subjects who undergo surgical removal of at least two third molars~* One of which must be a partial or full bony mandibular impaction~* Subjects must have at least moderate baseline pain (a score of 2 on the categorical pain severity rating scale) confirmed by a score of at least 50 mm on the 100-mm visual analog scale-pain severity rating scale (VAS-PSR)~Exclusion Criteria:~* Acute localized dental infection at the time of surgery that could confound the post-surgical evaluation~* Presence or history of any significant organ disease~* Use of prescription or OTC first generation antihistamines~* Females who are pregnant, lactating or of childbearing potential and not using a medically approved method to prevent pregnancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen 600 mg extended release (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa~Exclusion Criteria:~* History of human immunodeficiency virus (HIV) or positive HIV serology at screening,~* Infected with hepatitis B or hepatitis C viruses.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): PF-06650833
- Cohort 2 (Type: EXPERIMENTAL): PF-6700841
- Cohort 3 (Type: EXPERIMENTAL): PF-06826647
- Cohort placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind Naltrexone in Kleptomania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. men and women age 21-75~2. current DSM-IV kleptomania.~Exclusion Criteria:~1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination~2. history of seizures~3. myocardial infarction within 6 months~4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential~5. clinically significant suicidality~6. current or recent (past 3 months) DSM-IV substance abuse or dependence~7. illegal substance within 2 weeks of study initiation~8. initiation of psychotherapy or behavior therapy from a mental health professional for the treatment of kleptomania within 3 months prior to study baseline~9. initiation of a psychotropic medication within 2 months prior to study inclusion~10. previous treatment with naltrexone~11. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Naltrexone
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status 1 or 2 patients patients scheduled for thyroidectomy~Exclusion Criteria:~* Severe cardiovascular disease history of motion sickness active status of upper respiratory infection allergy to dexmedetomidine patients who cannot understand Korean

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: EXPERIMENTAL): We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
- saline (Type: PLACEBO_COMPARATOR): We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions.~2. Participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures.~3. Male or female participants aged 18-75 (including 18 and 75 years old).~4. Confirmed SARS-CoV-2 infection 120 hours prior to randomization.~5. Initial onset of COVID-19 symptoms/signs within 48 hours before randomization.~6. Fertile participants must agree to take effective contraceptive measures.~Exclusion Criteria:~1. Patients with severe or critical COVID-19 who currently require hospitalization, or patients who are expected to develop into severe or critical disease and require hospitalization within 48h after randomization.~2. Difficulty swallowing or a history of gastrointestinal diseases that seriously affect drug absorption.~3. Active liver disease, or obvious abnormal liver function (ALT or AST ≥ 3ULN, or total bilirubin ≥ 2ULN).~4. WBC \>1ULN, or NEU \<0.5ⅹ109/L.~5. Receiving dialysis or have known moderate to severe renal impairment (eGFR\<60mL/min/1.73m2).~6. Other suspected or confirmed systemic infections.~7. Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are highly dependent on CYP3A4 or CYP2C19 for clearance.~8. Prior or anticipated receipt of any vaccine within 28 days prior to enrollment and during study period.~9. Use of antivirals against SARS-CoV-2 within 7 days prior to enrollment.~10. Weight≤40kg.~11. Pregnant, lactating women or those with a positive pregnancy test (sterilized or postmenopausal women may not have a pregnancy test).~12. Previous administration with any investigational drug within 3 months before the study drug administration.~13. Participants who are judged by the investigator to be unsuitable to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RAY1216 (Type: EXPERIMENTAL): Participants received 400mg RAY1216 tablet orally three times daily for 5 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received 400mg placebo orally three times daily for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female age between 2 and 65 years (inclusive)~* Parasites visualized on splenic aspiration~* Signs and symptoms compatible with visceral leishmaniasis (e.g. fever, splenomegaly, anaemia, weight loss, leucopenia, thrombocytopenia)~* Confirmed diagnosis of VL by visualization of parasites on splenic/bone marrow aspirate~* Fever for at least 2 weeks~* Written informed consent from the patient/or from parent or guardian if under 18 years old~Exclusion Criteria:~* Hemoglobin \< 6 g/dl~* White blood cell count \< 1000/mm3~* Platelets \<50,000~* Prothrombin time \> 5 sec above control~* ASAT \> 3 times the upper limit of normal~* Serum creatinine or BUN \> 1.5 times the upper limit of normal~* Malaria~* Tuberculosis~* HIV positive serology~* Lactation, pregnancy~* Refusing contraception method during treatment period plus 3 months~* Any medical condition(s) that upon judgment of physician may affect the safety of the patient when treated with study drugs~* Any concomitant drug that is nephrotoxic

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete